Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.
Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio.
Wexner Medical Center at The Ohio State University, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, Columbus, Ohio.
Astrazeneca Ltd., Oncology iMed, Macclesfield, UK.
Center for Biostatistics, The Ohio State University, Columbus, Ohio.
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- Published Article
Pediatric Blood & Cancer
Wiley (John Wiley & Sons)
- Publication Date
Oct 01, 2015
Selumetinib suppressed TORC1 signaling in the context of BRAF mutation. Selumetinib caused a rapid downregulation of FANCD2 and markedly potentiated the effect of XRT. These data suggest the possibility of potentiating the effect of XRT selectively in tumor cells by MEK inhibition in the context of mutant BRAF or maintaining tumor control at lower doses of XRT that would decrease long-term sequelae.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/25981859